Vasculitis
Marco A Alba, MD, PhD MA_ALBA_vascul
5 years ago
@drdavidliew @VasculitisUMCG @RheumNow Dear David, thanks for your interest in our abstract #ACR20. This is based on some intriguing findings found in our previous observational study https://t.co/HKm53j2xou Still a work in progress but the potential adjunctive anti-inflammatory effect of ARBs seems attractive.
Adam Kilian MD KilianMD
5 years ago
Pearls from @anisha_dua for differentiating atherosclerosis vs. vasculitis inflammation on imaging:
1. Look at the Axillary arteries - they tend to be less likely affected by atherosclerosis
2. Vasculitic lesions tend to be concentric & longer/continuous
#ACR20 #RheumTwitter
Emily Littlejohn ELittlejohnDO
5 years ago
We need to start utilizing and normalizing anti phosphatidylserine/prothrombin antibody ordering in clinical practice #ACR20 https://t.co/LeeHnuX9x0
E. Sloan esloanmd
5 years ago
Nice succinct review of recent DOAC studies in #APS by Dr. Ortel. Recommends avoiding DOACs in triple positive pts #antiphospholipid #ACR20 https://t.co/Hc6ye3mvTg
David Liew drdavidliew
5 years ago
Should ARBs be adjunct Rx in GCA?
Plausible target:
- previous pharmacoepi
- ATII expressed in GCA inflamm lesions
- ATII induced pro-inflamm in PBMC/co-cultured VSMC
- steroids modulate ATII expression in GCA TA ex vivo
Maybe worth testing?
Cid et al #ACR20 ABST0510 @RheumNow https://t.co/mNNzZVYe7g
Olga Petryna DrPetryna
5 years ago
@RheumNow #acr20 abs0622 infection induced MPO anca vasc: most common triggers viruses(35.2%), mycobacterial (29.4%)& bacterial inf (29.4%). Onset 3 mo post inf. (70.5%) renal involvement, w/ biopsy-proven GN in 53%. 17.6%died. Rx steroids+abx, CYC in 47%.
sheila RHEUMarampa
5 years ago
Low pre🤰c3/c4 levels assoc'd w/ ⬆ risk of adverse obstetric outcomes in women w/ aPL w/or w/o APS. Pts w/ triple+ aPL and ⬇ c3/c4 predicts a worse prognosis. @RheumNow #ACR20 https://t.co/Cd2TQBfXSe
David Liew drdavidliew
5 years ago
What happens long-term in Kawasaki disease now? Has IVIG availability fixed this?
Pop-based cohort, long follow-up.
Turns out cardiac event risk, whilst greatest early, continues >10y after - even in those w/o coronary aneurysms
@SickKidsNews @McMasterU #ACR20 ABST0937 @RheumNow https://t.co/1T6JmwhXNb
KenWarringtonMD MdWarrington
5 years ago
Ground-breaking news... the end of #glucocorticoid use in #AAV?
very exciting to reduce GC toxicity! https://t.co/43eCofpOIX
KenWarringtonMD MdWarrington
5 years ago
Use of diagnostic imaging for #GCA is ⬆️
Use of temporal artery biopsy⬇️
data from #MayoClinicRheumatology @garveythomasma1
#acr20 #RheumTwitter https://t.co/kQTg5FTlVq
Avacopan - C5a Receptor Inhibitor - in ANCA-Associated Vasculitis: Dr. Arthur Kavanaugh
San Diego-based rheumatologist Dr. Arthur Kavanaugh takes a closer look at plenary session Abstract #0432 presented Friday at ACR 2020.
Large vessel vasculitis (LVV) and CNS vasculitis are rare subsets of vasculitis. The challenges related to these diseases are well known to the rheumatologists who treat around the world. There are many articles stating that a delay in diagnosis of these diseases leads to increased morbidity and mortality.
Dr Sarah Mackie Sarah_L_Mackie
5 years ago
@drdavidliew @MGHrheumatology @RheumNow That is so interesting. Haptoglobin first described by Paolaggi et al in early 1980s as having potential to monitor PMR/GCA even when ESR normalised. See link here...
https://t.co/ERkhUwssox
David Liew drdavidliew
5 years ago
If TCZ blunts CRP a lot/ESR a fair bit, how can we pick GCA relapses in pts on TCZ?
Cool tech (mass spec w tandem mass tag multiplex) on GiACTA samples. Of 344 candidate proteins, guess what ranked highest?
Haptoglobin.
Let's validate!
@MGHrheumatology #ACR20 ABST0513 @RheumNow https://t.co/ErmqZuf2iu
Poster Hall